Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Chemotherapy in HNSCC Neoadjuvant/Conversion Therapy
NCT06218004Phase 2Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in head and neck squamous cell carcinoma (HNSCC). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06218004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218004.